The question of whether to switch patients from a reference biologic to an available biosimilar has been the subject of extensive debate, especially in patients with inflammatory bowel disease (IBD), an indication in which evidence on relevant clinical outcomes after switching is limited.
The question of whether to switch patients from a reference biologic to an available biosimilar has been the subject of extensive debate, especially in patients with inflammatory bowel disease (IBD), an indication in which evidence on relevant clinical outcomes after switching is limited.
A newly published review sought to evaluate whether patients with IBD should be switched from the reference infliximab to CT-P13 (sold in the United States as Inflectra and in the European Union as Remsima). The researchers identified 24 studies, including 1326 patients with IBD, evaluating switches between the reference and the biosimilar.
Among these patients, disease control (defined as no evidence of disease worsening after a switch) was confirmed in 1163 patients (weighted mean [WM], 88%; 95% CI, 86%-89%). When only studies that included a follow-up from 4 to 8 months post-switch were included, the WM rose to 90% (95% CI, 89%-92%). When subanalyses were conducted in patients with Crohn disease (CD) and ulcerative colitis (UC), respectively, the WM were 86% (82%-89%) and 93% (89%-96%).
No unexpected adverse event (AEs) were reported in any of the included studies, and upon further evaluation, no differences in AEs were reported after switching versus before switching, and in the 1 randomized controlled trial included in the review (the NOR-SWITCH study), the frequencies of reported AEs were not different in patients who switched versus patients who did not switch.
Additionally, say the authors, no new safety or immunogenicity signals or changes in efficacy arose after a singled switch, though data on multiple switches are few. Because multiple switches could increase the likelihood of patients developing anti-drug antibodies, say the authors, repeated switching should be discouraged.
“The risks of switching to biosimilar products seem to be theoretical and not supported by the limited real world safety experience so far,” write the authors. They add that, in accordance with the European Crohn’s and Colitis Organisation’s position, a switch to the biosimilar from the reference infliximab is acceptable if a patients’ IBD disease is well controlled with the reference.
The decision to switch should be left in the hands of the treating physician, and physicians who do decide to switch a patient’s therapy must take an active role in educating the patient about the rationale for the change of therapy.
Reference
Gisbert JP, Chaparro M. Switching from an originator anti-TNF to a biosimilar in patients with inflammatory bowel disease: Can it be recommended? A systematic review. Gastroenterol Hepato. 2018:S0210-5705(18):30108-0. doi: 10.1016/j.gastrohep.2018.04.005.
Biosimilars Gastroenterology Roundup: March 2025
April 1st 2025As the biosimilar industry celebrates a decade of growth, the market continues to evolve with expanded treatment options, cost savings, and a flurry of new competitors—yet regulatory challenges, market dynamics, and patient accessibility remain key hurdles to unlocking its full potential.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Patients With IBD Maintain Therapy 2 Years Post Switching to Infliximab Biosimilar
March 23rd 2025People with inflammatory bowel disease (IBD) who switched to the infliximab biosimilar CT-P13 had higher treatment persistence (84% and 91%) than those new to infliximab (66% and 53%), with no new safety concerns.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Comparable Pregnancy and Infant Milestones With Infliximab Biosimilars vs Originator in IBD
March 15th 2025A study evaluating pregnancy outcomes and infant developmental milestones found similar outcomes between pregnant women with inflammatory bowel disease (IBD) who received reference infliximab and those who received a biosimilar.